Related Experiment Video

Updated: Jul 17, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Targeted therapy for colorectal cancer

Jimmy Hwang1, John L Marshall

  • 1Lombardi Comprehensive Cancer Center, 3800 Reservoir Road NW, Washington, DC 20007, USA.

Current Opinion in Investigational Drugs (London, England : 2000)
|January 11, 2007
PubMed

Insights

Targeted therapies revolutionizing colorectal cancer treatment have emerged, focusing on vascular endothelial growth factor and epidermal growth factor receptor. These novel agents show significant anticancer activity and are now approved for clinical use.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Colorectal cancer treatment has significantly advanced in the past decade.
  • Targeted therapies represent a major breakthrough, focusing on specific molecular pathways.
  • Key targets include vascular endothelial growth factor and epidermal growth factor receptor.

Purpose of the Study:

  • To review data supporting the use of targeted agents in colorectal cancer.
  • To discuss the efficacy and clinical approval of novel targeted therapies.
  • To explore future directions for targeted agents and pathways in colorectal cancer treatment.

Main Methods:

  • Review of clinical trial data for targeted agents in colorectal cancer.
  • Analysis of approved targeted therapies and their demonstrated anticancer activity.
  • Discussion of emerging research on novel agents and pathways.

Main Results:

  • Targeted agents targeting vascular endothelial growth factor and epidermal growth factor receptor have shown significant anticancer activity.
  • Several novel targeted agents have been approved for clinical use in colorectal cancer.
  • Clinical trials demonstrate the efficacy of these targeted approaches.

Conclusions:

  • Targeted therapy has revolutionized colorectal cancer treatment.
  • Vascular endothelial growth factor and epidermal growth factor receptor inhibitors are key components of modern colorectal cancer therapy.
  • Future research holds promise for further advancements in targeted colorectal cancer treatment.

More Related Videos

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.